Drugs / AG013
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00938080 | Sep 2009 → Sep 2012 | chemotherapy-induced oral mucositis | ActoGeniX N.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03234465 | Jul 2017 → Mar 2020 | mucositis | Oragenics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00938080 ↗ |
| Modality | Other / unclassified | “genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1” NCT00938080 ↗ |
| Route | Topical | “Topically Applied AG013” NCT00938080 ↗ |